Stay updated with breaking news from Previously Treated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.
With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.
Aaron Lisberg, MD, provides a look at an upcoming Rapid Readout program looking at the results of the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.
Media contact: Investor contact: ...